Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed its fiscal 2025 10-K annual report with the SEC on Feb 5, 2026. It reported revenue of $52M (−18.5% year over year) and net income of −$266M.
- Top risk flagged: Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease
FY2025 key financial metrics · XBRL
- Revenue
- $52M
- −18.5% YoY
- Net income
- −$266M
- −37.4% YoY
- Operating margin
- -519.8%
- −250.2 pp YoY
- EPS (diluted)
- −$1.42
- −16.4% YoY
- ROE
- -40.6%
- +20.7 pp YoY
- Operating cash flow
- −$205M
- −52.1% YoY
Source: XBRL data from the OCULAR THERAPEUTIX, INC (OCUL) FY2025 10-K on SEC EDGAR. USD.
OCULAR THERAPEUTIX, INC FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Integrated biopharmaceutical company developing ELUTYX hydrogel-based ocular drug delivery platform for retina diseases
- New emphasis on AXPAXLI (OTX-TKI), a Phase 3 axitinib intravitreal hydrogel implant targeting wet AMD and diabetic retinal disease with registrational trials SOL and HELIOS
- Strategic shift: Expansion from commercial DEXTENZA steroid to late-stage novel AXPAXLI candidate with accelerated NDA timeline via 505(b)(2) pathway
- Quantitative highlight: SOL-1 trial randomized 344 subjects by Dec 2024; SOL-R trial randomized 631 subjects by Nov 2025 across US, Argentina, India, Australia
- Noteworthy fact: ELUTYX technology used in 5 million+ patients since 1992; DEXTENZA implanted in nearly 750,000 eyes with adverse events in 0.02% patients
Management Discussion & Analysis
- Revenue $51.9M in 2025 vs $63.7M in 2024 and $58.4M in 2023, declining due to decreased DEXTENZA sales
- Net loss widened to $265.9M in 2025 from $193.5M in 2024 and $80.7M in 2023; operating expenses $322.0M in 2025
- Operating margin negative, reflecting sustained losses and increasing R&D and commercial expenses
- Cash and cash equivalents $737.1M at Dec 31, 2025; financing activities provided $561.7M in 2025 including $445.6M from 2025 stock offering
- Management expects cash to fund operations into 2028 but anticipates need for additional funds to commercialize AXPAXLI if approved
Risk Factors
- Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease
- Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales
- Operational vulnerability: reliance on scaling manufacturing and commercial capabilities for DEXTENZA and AXPAXLI commercialization
- Competitive risk: uncertainty if AXPAXLI achieves sufficient market acceptance against other treatments for wet AMD and NPDR
- Financial risk: net losses $265.9M in 2025, accumulated deficit $1.157B, may require additional capital raising causing dilution or operational constraints
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.